Two drugs, recombinant human thrombopoietin (rhTPO) and recombinant human interleukin-11 (rhIL-11) have been approved by the National Medical Products Administration (NMPA) for the treatment of chemotherapy- or chemoradiotherapy-induced thrombocytopenia. This evidence concerns the gene THPO and Thrombocytopenia.